KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2025)

Historic Return on Sales for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 188.82%.

  • CRISPR Therapeutics AG's Return on Sales fell 1866100.0% to 188.82% in Q4 2025 from the same period last year, while for Dec 2025 it was 174.97%, marking a year-over-year decrease of 1640300.0%. This contributed to the annual value of 174.96% for FY2025, which is 1640300.0% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Return on Sales stood at 188.82% for Q4 2025, which was down 1866100.0% from 119.73% recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Return on Sales high stood at 0.84% for Q2 2021, and its period low was 18809.5% during Q4 2022.
  • In the last 5 years, CRISPR Therapeutics AG's Return on Sales had a median value of 155.76% in 2021 and averaged 1186.56%.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Return on Sales plummeted by -187985500bps in 2022, and later soared by 188097900bps in 2023.
  • CRISPR Therapeutics AG's Return on Sales (Quarter) stood at 10.95% in 2021, then crashed by -171671bps to 18809.5% in 2022, then soared by 100bps to 0.29% in 2023, then crashed by -860bps to 2.21% in 2024, then plummeted by -8429bps to 188.82% in 2025.
  • Its Return on Sales was 188.82% in Q4 2025, compared to 119.73% in Q3 2025 and 233.81% in Q2 2025.